logo
Share SHARE
FONT-SIZE Plus   Neg

Royal DSM To Buy Kensey Nash For $38.5/Shr - Quick Facts

Royal DSM (RDSMY.PK) has reached a definitive agreement with Kensey Nash Corp. (KNSY), pursuant to which DSM would acquire Kensey Nash through a cash tender offer, followed by a merger with an unit of DSM, for $38.50 in cash per share for total enterprise value of around $360 million. The agreed price represents a premium of 33% to Kensey Nash's closing share price of $29.01 on May 2, 2012. The transaction may be complete around the end of second quarter of 2012.

Kensey Nash's board has unanimously recommended its stockholders to accept the offer and tender their shares into the offer when it is made. The tender offer is expected to begin in May. The transaction is not subject to a financing condition, and DSM plans to finance the acquisition from existing cash. DSM anticipates the transaction to be accretive to earnings from 2013 onwards.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Rare commodities are worth more than good is a Chinese adage. And more so when it is in the sought-after drug space. Rare and ultra-rare diseases, also called orphan and ultra-orphan diseases, as the names imply, affect very small numbers of patients. So why the clamor? Shares of steel giant ArcelorMittal were losing around 4 percent in the early morning trading in Amsterdam after the company reported sharp decline in first-quarter EBITDA, a key earnings metric, as sales were weak with lower prices and production. Net loss, however, narrowed from last year. The company also confirmed its forecast for annual EBITDA, which is lower than last year. As the din settles down on a dismal quarter at one of the world's exciting tech company, it is time to sit back and take stock of what went wrong and will the wrong be righted in the near term?
comments powered by Disqus
Follow RTT